The societal costs of multiple sclerosis in Lebanon: a cross-sectional study

References

• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012 Jun;18(2 Suppl):7–15.
   PubMed Web of Science ®Google Scholar
• Calabrese P, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Switzerland. Mult Scler. 2017 Aug;23(2_suppl):192–203.
   PubMed Web of Science ®Google Scholar
• Boyko A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Russia. Mult Scler. 2017 Aug;23(2_suppl):155–165.
   PubMed Web of Science ®Google Scholar
• Owens GM, Olvey EL, Skrepnek GH, et al. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S41–53.
   PubMed Web of Science ®Google Scholar
• Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11(7):e0159129.
   PubMed Web of Science ®Google Scholar
• Paz-Zulueta M, Parás-Bravo P, Cantarero-Prieto D, et al. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102162.
   PubMed Web of Science ®Google Scholar
• Dahham J, Rizk R, Kremer I, et al. Economic burden of multiple sclerosis in low- and middle-income countries: a systematic review. Pharmacoeconomics. 2021 Jul;39(7):789–807.
   PubMed Web of Science ®Google Scholar
• Dahham J, Kremer I, Hiligsmann M, et al., Valuation of costs in health economics during financial and economic crises: a case study from Lebanon. Appl Health Econ Health Policy. 2023. 21(1): 31–38.
   PubMed Web of Science ®Google Scholar
• MoPH. 2022. Lebanon national health strategy-vision 2030. Beirut: Republic of Lebanon Ministry of Public Health. Lebanon National Health Strategy-Vision 2030 (moph.gov.lb):Accessed 2023 Feb 10.
   Google Scholar
• Khalife J, Rafeh N, Makouk J, et al. Hospital contracting reforms: the Lebanese ministry of public health experience. Health Syst Reform. 2017;3(1):34–41.
   PubMed Web of Science ®Google Scholar
• Zeineddine M, Hajje AA, Hussein A, et al. Epidemiology of multiple sclerosis in Lebanon: a rising prevalence in the Middle East. Mult Scler Relat Disord. 2021 Jul;52:102963.
   PubMedGoogle Scholar
• Yamout B, Alroughani R, Al-Jumah M, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin. 2015;31(7):1349–1361.
   PubMed Web of Science ®Google Scholar
• Dahham J, Rizk R, Hiligsmann M, et al. The Economic and societal burden of multiple sclerosis on Lebanese society: a cost-of-illness and quality of life study protocol. Expert Rev Pharmacoecon Outcomes Res. 2021 Nov 26;22:1–8.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162–173.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Riewpaiboon A. Measurement of costs for health economic evaluation. J Med Assoc Thai. 2014 May;97(Suppl 5):S17–26.
   PubMedGoogle Scholar
• Kobelt G, Thompson A, Berg J, et al., New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017. 23(8): 1123–1136.
   PubMed Web of Science ®Google Scholar
• MoPH. Drugs public price list 2021: republic of Lebanon Ministry of Public Health. Available from: https://www.moph.gov.lb/en/Drugs/index/3/4848/lebanon-national-drugs-database#/en/view/58026/drugs-public-price-list cited 2022 Jul 10
   Google Scholar
• Koopmanschap MA, van Exel JN, van den Berg B, et al. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26(4):269–280.
   PubMed Web of Science ®Google Scholar
• Hodgson TA. Costs of illness in cost-effectiveness analysis. A review of the methodology. Pharmacoeconomics. 1994 Dec;6(6):536–552.
   PubMed Web of Science ®Google Scholar
• WB. PPP conversion factor, GDP (LCU per international $) - Lebanon: the world bank. https://data.worldbank.org/indicator/PA.NUS.PPP?locations=LB cited 2022 Aug 12
   Google Scholar
• WB (2022) GDP per capita, PPP (current international $) - Lebanon. The World Bank. https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?locations=LB. cited 12 August 2022
   Google Scholar
• WB (2022) GDP per capita (current US$) - Lebanon. The World Bank. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=LB. cited 2022 Aug 12
   Google Scholar
• CAS (2022) Consumer Price Index CPI. Central Administration of Statistics. http://cas.gov.lb/index.php/economic-statistics-en. cited 2022 Aug 12
   Google Scholar
• Rasmussen PV, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Denmark. Mult Scler. 2017 Aug;23(2_suppl):53–64.
   PubMed Web of Science ®Google Scholar
• Blahova Dusankova J, Kalincik T, Dolezal T, et al. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler. 2012 May;18(5):662–668.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225–240.
   PubMed Web of Science ®Google Scholar
• Bizri AR, Khachfe HH, Fares MY, et al. COVID-19 pandemic: an insult over injury for Lebanon. J Community Health. 2021 Jun;46(3):487–493.
   PubMed Web of Science ®Google Scholar
• Devi S. Lebanon faces humanitarian emergency after blast. Lancet. 2020 Aug 15;396(10249):456.
   PubMed Web of Science ®Google Scholar
• Naja F, Alameddine M, Itani L, et al. The use of complementary and alternative medicine among Lebanese adults: results from a national survey. Evid Based Complement Alternat Med. 2015;2015:682397.
   PubMed Web of Science ®Google Scholar
• Rizk R, Hiligsmann M, Karavetian M, et al. A societal cost-of-illness study of hemodialysis in Lebanon. J Med Econ. 2016 Dec;19(12):1157–1166.
   PubMed Web of Science ®Google Scholar
• Kharroubi S, Naja F, Diab-El-Harake M, et al. Food insecurity pre- and post the COVID-19 pandemic and economic crisis in Lebanon: prevalence and projections. Nutrients. 2021 Aug 27;13:9.
   Web of Science ®Google Scholar
• Lavelle TA, D’Cruz BN, Mohit B, et al. Family spillover effects in pediatric cost-utility analyses. Appl Health Econ Health Policy. 2019 Apr;17(2):163–174.
   PubMed Web of Science ®Google Scholar
• Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med. 2017 Dec 8;15(1):216.
   PubMedGoogle Scholar
• Turner HC, Lauer JA, Tran BX, et al. Adjusting for inflation and currency changes within health economic studies. Value Health. 2019 Sep;22(9):1026–1032.
   PubMed Web of Science ®Google Scholar
• J H, S G (2011) Handbook for systematic reviews of interventions. The Cochrane Collaboration. https://handbook-5-1.cochrane.org/. cited 2022 Jun 14
   Google Scholar
• Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009 Oct;15(10):1175–1182.
   PubMedGoogle Scholar
• Daccache C, Rizk R, Dahham J, et al. Economic evaluation guidelines in low- and middle-income countries: a systematic review. Int J Technol Assess Health Care. 2021 Dec 21;38(1):e1.
   PubMed Web of Science ®Google Scholar